23andMe Reports Q1 Revenue Drop, Narrows Losses
23andMe's Q1 revenue declines by 34% but narrows losses. Focus on AI and genetic studies drives future growth.
- Latest
- Trending
23andMe's Q1 revenue declines by 34% but narrows losses. Focus on AI and genetic studies drives future growth.
The Open Medical-LLM leaderboard offers valuable insights into AI-related medical devices, although none of the approved devices use generative AI.
A new research project shows that smaller models can achieve competitive results. Check out the Paper and Model for more ...
Canadian cannabis producer Organigram Holdings Inc. has made its first shipment of bulk dried flower to Sanity Group, entering the ...
Biopharmaceutical company Atossa Genetics receives Buy rating from H.C. Wainwright, with a new price target of $4.00. The company's promising ...
Learning and playing a musical instrument can strengthen the brain, reduce the risk of dementia, and improve executive function and ...
Private equity and venture capital fundraising are expected to reach 2021 highs again in 2028, despite ongoing challenges and uncertainties ...
OnCusp Therapeutics raises $100M in Series A funding to advance its research and development efforts in innovative therapeutics. #biotech #funding
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.